Iambic Therapeutics launches next-gen Enchant AI model and inks R&D partnership with AbbVie
Iambic Therapeutics, a San Diego‑based biotech founded in 2019, announced the release of the next generation of its Enchant artificial‑intelligence model.
The updated model is intended to enhance the company’s drug‑discovery workflows, building on the capabilities of earlier versions.
In parallel, Iambic disclosed an R&D partnership with AbbVie. The agreement will give AbbVie access to Iambic’s AI platform to support its research efforts, though specific terms were not disclosed.
The combined announcement highlights Iambic’s growing role in applying AI to pharmaceutical research and its expanding collaborations with major industry players.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Iambic signs AbbVie deal, releases next generation of Enchant model”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that